Abstract
Dilated cardiomyopathy (DCM) is the leading cause of sudden cardiac death (SCD) and heart failure (HF) in children and adults worldwide, and it is also the main indication of heart transplantation. DCM remains a significant cause of heart transplantation despite recent improvements in treatment, which is related to the enormous financial strain placed on the world's healthcare system. Therefore, determining the prognosis of individuals with DCM is crucial for providing them with a customized course of treatment. Genetic testing, microvolt T-wave alternation, and late gadolinium-enhanced cardiac magnetic resonance imaging have developed into potent methods for predicting the occurrence of sudden cardiac death and optimizing patient selection. Despite the availability of numerous novel diagnostic techniques, further tests are still required to enhance or partially substitute current methods of risk categorization. As a result, biomarkers are robust and straightforward tools that can identify people at risk for unfavorable cardiovascular events. Thus, this article aims to review the state of the research on biomarkers for DCM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
